Your session is about to expire
← Back to Search
Device
MST for Parkinson's Disease (MST-PD Trial)
N/A
Waitlist Available
Led By Fidel Vila-Rodriguez, MD, PhD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights
No Placebo-Only Group
Summary
This trial tests Magnetic Seizure Therapy (MST) for treating depression in patients with Parkinson's Disease. MST uses magnetic pulses to induce controlled seizures, which can help improve mood. The trial aims to see if MST is feasible and safe for these patients. MST is a new treatment that uses magnetic fields to induce therapeutic seizures and has shown promise as an alternative to electroconvulsive therapy (ECT) with potentially fewer cognitive side effects.
Eligible Conditions
- Parkinson's Disease
- Depression
- Overactive Bladder
- Movement Disorders
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 18 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Feasibility of using MST to treat dPDT for depression in Parkinson's disease: recruitment
Feasibility of using MST to treat dPDT for depression in Parkinson's disease: retention
Feasibility of using MST to treat dPDT for depression in Parkinson's disease: side effects
Secondary study objectives
Efficacy information to plan future definite trial
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Magnetic Seizure TherapyExperimental Treatment1 Intervention
MST treatments will be administered using the MagPro XP MST with Cool TwinCoil.
Find a Location
Who is running the clinical trial?
University of British ColumbiaLead Sponsor
1,466 Previous Clinical Trials
2,485,436 Total Patients Enrolled
Fidel Vila-Rodriguez, MD, PhDPrincipal InvestigatorUniversity of British Columbia
2 Previous Clinical Trials
520 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have any of the heart-related risk factors mentioned in the Revised Cardiac Risk Index Score.You started taking certain types of medications for mental health less than 4 weeks ago.You are 50 years of age or older.You are currently experiencing severe mental health issues that affect your thoughts and behaviors.You have a metal object in or near your head that can't be safely taken out.You are taking a high dose of a medication called benzodiazepine or anticonvulsants, which may affect the effectiveness of the study treatment.You have been diagnosed with Parkinson's disease using specific criteria from the UK Brain Bank.You have Parkinson's disease at a moderate stage.You have been diagnosed with a current major depressive episode using the MINI International Neuropsychiatric Interview, Version 6.You have a score of 22 or higher on a test that measures how severe your depression is.You are approved by a psychiatrist and an anaesthesiologist to receive convulsive therapy.If you are taking antidepressant medication, you must be willing to continue taking the same medication during the study.Meet the safety criteria for the study.You have been diagnosed with a serious memory and thinking disorder other than Parkinson's disease, or your Montreal Cognitive Assessment score is less than 21.
Research Study Groups:
This trial has the following groups:- Group 1: Magnetic Seizure Therapy
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger